(NASDAQ: FBLG) Fibrobiologics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Fibrobiologics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast FBLG's revenue for 2028 to be $624,985,999, with the lowest FBLG revenue forecast at $624,985,999, and the highest FBLG revenue forecast at $624,985,999. On average, 1 Wall Street analysts forecast FBLG's revenue for 2029 to be $637,552,741, with the lowest FBLG revenue forecast at $637,552,741, and the highest FBLG revenue forecast at $637,552,741.
In 2030, FBLG is forecast to generate $1,619,434,230 in revenue, with the lowest revenue forecast at $1,619,434,230 and the highest revenue forecast at $1,619,434,230.